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Abstract: In response to recommendations to redefine statistical significance to p ≤ .005, we 8 
propose that researchers should transparently report and justify all choices they make when 9 
designing a study, including the alpha level. 10 
  11 
11 
Justify Your Alpha 1 
 2 
Benjamin et al.1 proposed changing the conventional “statistical significance” threshold (i.e., 3 
the alpha level) from p ≤ .05 to p ≤ .005 for all novel claims with relatively low prior odds. 4 
They provided two arguments for why lowering the significance threshold would 5 
“immediately improve the reproducibility of scientific research.” First, a p-value near .05 6 
provides weak evidence for the alternative hypothesis. Second, under certain assumptions, 7 
an alpha of .05 leads to high false positive report probabilities (FPRP2; the probability that a 8 
significant finding is a false positive).  9 
 10 
We share their concerns regarding the apparent non-replicability of many scientific studies, 11 
and agree that a universal alpha of .05 is undesirable. However, redefining “statistical 12 
significance” to a lower, but equally arbitrary threshold, is inadvisable for three reasons: (1) 13 
there is insufficient evidence that the current standard is a “leading cause of non-14 
reproducibility”1; (2) the arguments in favor of a blanket default of p ≤ .005 do not warrant the 15 
immediate and widespread implementation of such a policy; and (3) a lower significance 16 
threshold will likely have negative consequences not discussed by Benjamin and colleagues. 17 
We conclude that the term “statistically significant” should no longer be used and suggest 18 
that researchers employing null hypothesis significance testing justify their choice for an 19 
alpha level before collecting the data, instead of adopting a new uniform standard. 20 
 21 
Lack of evidence that p ≤ .005 improves replicability 22 
 23 
Benjamin et al.1 claimed that the expected proportion of replicable studies should be 24 
considerably higher for studies observing p ≤ .005 than for studies observing .005 < p ≤ .05, 25 
due to a lower FPRP. Theoretically, replicability is related to the FPRP, and lower alpha 26 
levels will reduce false positive results in the literature. However, in practice, the impact of 27 
lowering alpha levels depends on several unknowns, such as the prior odds that the 28 
12 
examined hypotheses are true, the statistical power of studies, and the (change in) behavior 1 
of researchers in response to any modified standards.  2 
 3 
An analysis of the results of the Reproducibility Project: Psychology3 showed that 49% 4 
(23/47) of the original findings with p-values below .005 yielded p ≤ .05 in the replication 5 
study, whereas only 24% (11/45) of the original studies with .005 < p ≤ .05 yielded p ≤ .05 6 
(χ2(1) = 5.92, p = .015, BF10 = 6.84). Benjamin and colleagues presented this as evidence of 7 
“potential gains in reproducibility that would accrue from the new threshold.” According to 8 
their own proposal, however, this evidence is only “suggestive” of such a conclusion, and 9 
there is considerable variation in replication rates across p-values (see Figure 1). 10 
Importantly, lower replication rates for p-values just below .05 are likely confounded by p-11 
hacking (the practice of flexibly analyzing data until the p-value passes the “significance” 12 
threshold). Thus, the differences in replication rates between studies with .005 < p ≤ .05 13 
compared to those with p ≤ .005 may not be entirely due to the level of evidence. Further 14 
analyses are needed to explain the low (49%) replication rate of studies with p ≤ .005, before 15 
this alpha level is recommended as a new significance threshold for novel discoveries 16 
across scientific disciplines. 17 
 18 
Weak justifications for the α = .005 threshold 19 
 20 
We agree with Benjamin et al. that single p-values close to .05 never provide strong 21 
“evidence” against the null hypothesis. Nonetheless, the argument that p-values provide 22 
weak evidence based on Bayes factors has been questioned4. Given that the marginal 23 
likelihood is sensitive to different choices for the models being compared, redefining alpha 24 
levels as a function of the Bayes factor is undesirable. For instance, Benjamin and 25 
colleagues stated that p-values of .005 imply Bayes factors between 14 and 26. However, 26 
these upper bounds only hold for a Bayes factor based on a point null model and when the 27 
p-value is calculated for a two-sided test, whereas one-sided tests or Bayes factors for non-28 
13 
point null models would imply different alpha thresholds. When a test yields BF = 25 the data 1 
are interpreted as strong relative evidence for a specific alternative (e.g., μ = 2.81), while a p 2 
≤ .005 only warrants the more modest rejection of a null effect without allowing one to reject 3 
even small positive effects with a reasonable error rate5. Benjamin et al. provided no 4 
rationale for why the new p-value threshold should align with equally arbitrary Bayes factor 5 
thresholds. We question the idea that the alpha level at which an error rate is controlled 6 
should be based on the amount of relative evidence indicated by Bayes factors. 7 
 8 
The second argument for α = .005 is that the FPRP can be high with α = .05. Calculating the 9 
FPRP requires a definition of the alpha level, the power of the tests examining true effects, 10 
and the ratio of true to false hypotheses tested (the prior odds). Figure 2 in Benjamin et al. 11 
displays FPRPs for scenarios where most hypotheses are false, with prior odds of 1:5, 1:10, 12 
and 1:40. The recommended p ≤ .005 threshold reduces the minimum FPRP to less than 13 
5%, assuming 1:10 prior odds (the true FPRP might still be substantially higher in studies 14 
with very low power). This prior odds estimate is based on data from the Reproducibility 15 
Project: Psychology3 using an analysis modelling publication bias for 73 studies6. Without 16 
stating the reference class for the “base-rate of true nulls” (e.g., does this refer to all 17 
hypotheses in science, in a discipline, or by a single researcher?), the concept of “prior odds 18 
that H1 is true” has little meaning. Furthermore, there is insufficient representative data to 19 
accurately estimate the prior odds that researchers examine a true hypothesis, and thus, 20 
there is currently no strong argument based on FPRP to redefine statistical significance. 21 
 22 
How a threshold of p ≤ .005 might harm scientific practice 23 
 24 
Benjamin et al. acknowledged that their proposal has strengths as well as weaknesses, but 25 
believe that its “efficacy gains would far outweigh losses.” We are not convinced and see at 26 
least three likely negative consequences of adopting a lowered threshold. 27 
 28 
14 
Risk of fewer replication studies. All else being equal, lowering the alpha level requires larger 1 
sample sizes and creates an even greater strain on already limited resources. Achieving 2 
80% power with α = .005, compared to α = .05, requires a 70% larger sample size for 3 
between-subjects designs with two-sided tests (88% for one-sided tests). While Benjamin et 4 
al. propose α = .005 exclusively for “new effects” (and not replications), designing larger 5 
original studies would leave fewer resources (i.e., time, money, participants) for replication 6 
studies, assuming fixed resources overall. At a time when replications are already relatively 7 
rare and unrewarded, lowering alpha to .005 might therefore reduce resources spent on 8 
replicating the work of others. More generally, recommendations for evidence thresholds 9 
need to carefully balance statistical and non-statistical considerations (e.g., the value of 10 
evidence for a novel claim vs. the value of independent replications). 11 
 12 
Risk of reduced generalisability and breadth. Requiring larger sample sizes across scientific 13 
disciplines may exacerbate over-reliance on convenience samples (e.g., undergraduate 14 
students, online samples). Specifically, without (1) increased funding, (2) a reward system 15 
that values large-scale collaboration, and (3) clear recommendations for how to evaluate 16 
research with sample size constraints, lowering the significance threshold could adversely 17 
affect the breadth of research questions examined. Compared to studies that use 18 
convenience samples, studies with unique populations (e.g., people with rare genetic 19 
variants, patients with post-traumatic stress disorder) or with time- or resource-intensive data 20 
collection (e.g., longitudinal studies) require considerably more research funds and effort to 21 
increase the sample size. Thus, researchers may become less motivated to study unique 22 
populations or collect difficult-to-obtain data, reducing the generalisability and breadth of 23 
findings. 24 
 25 
Risk of exaggerating the focus on single p-values. Benjamin et al.’s proposal risks (1) 26 
reinforcing the idea that relying on p-values is a sufficient, if imperfect, way to evaluate 27 
findings, and (2) discouraging opportunities for more fruitful changes in scientific practice 28 
15 
and education. Even though Benjamin et al. do not propose p ≤ .005 as a publication 1 
threshold, some bias in favor of significant results will remain, in which case redefining p ≤ 2 
.005 as "statistically significant" would result in greater upward bias in effect size estimates. 3 
Furthermore, it diverts attention from the cumulative evaluation of findings, such as 4 
converging results of multiple (replication) studies. 5 
 6 
No one alpha to rule them all 7 
 8 
We have two key recommendations. First, we recommend that the label “statistically 9 
significant” should no longer be used. Instead, researchers should provide more meaningful 10 
interpretations of the theoretical or practical relevance of their results. Second, authors 11 
should transparently specify—and justify—their design choices. Depending on their choice of 12 
statistical approach, these may include the alpha level, the null and alternative models, 13 
assumed prior odds, statistical power for a specified effect size of interest, the sample size, 14 
and/or the desired accuracy of estimation. We do not endorse a single value for any design 15 
parameter, but instead propose that authors justify their choices before data are collected. 16 
Fellow researchers can then evaluate these decisions, ideally also prior to data collection, 17 
for example, by reviewing a Registered Report submission7. Providing researchers (and 18 
reviewers) with accessible information about ways to justify (and evaluate) design choices, 19 
tailored to specific research areas, will improve current research practices. 20 
 21 
Benjamin et al. noted that some fields, such as genomics and physics, have lowered the 22 
“default” alpha level. However, in genomics the overall false positive rate is still controlled at 23 
5%; the lower alpha level is only used to correct for multiple comparisons. In physics, 24 
researchers have argued against a blanket rule, and for an alpha level based on factors 25 
such as the surprisingness of the predicted result and its practical or theoretical impact8. In 26 
non-human animal research, minimizing the number of animals used needs to be directly 27 
balanced against the probability and cost of false positives. Depending on these and other 28 
16 
considerations, the optimal alpha level for a given research question could be higher or 1 
lower than the current convention of .059,10,11. 2 
 3 
Benjamin et al. stated that a “critical mass of researchers” endorse the standard of a p ≤ 4 
.005 threshold for “statistical significance.” However, the presence of a critical mass can only 5 
be identified after a norm has been widely adopted, not before. Even if a p ≤ .005 threshold 6 
were widely accepted, this would only reinforce the misconception that a single alpha level is 7 
universally applicable. Ideally, the alpha level is determined by comparing costs and benefits 8 
against a utility function using decision theory12. This cost-benefit analysis (and thus the 9 
alpha level)13 differs when analyzing large existing datasets compared to collecting data from 10 
hard-to-obtain samples. 11 
 12 
Conclusion 13 
 14 
Science is diverse, and it is up to scientists to justify the alpha level they decide to use. As 15 
Fisher noted14: "...no scientific worker has a fixed level of significance at which, from year to 16 
year, and in all circumstances, he rejects hypotheses; he rather gives his mind to each 17 
particular case in the light of his evidence and his ideas." Research should be guided by 18 
principles of rigorous science15, not by heuristics and arbitrary blanket thresholds. These 19 
principles include not only sound statistical analyses, but also experimental redundancy 20 
(e.g., replication, validation, and generalisation), avoidance of logical traps, intellectual 21 
honesty, research workflow transparency, and accounting for potential sources of error. 22 
Single studies, regardless of their p-value, are never enough to conclude that there is strong 23 
evidence for a substantive claim. We need to train researchers to assess cumulative 24 
evidence and work towards an unbiased scientific literature. We call for a broader mandate 25 
beyond p-value thresholds whereby all justifications of key choices in research design and 26 
statistical practice are transparently evaluated, fully accessible, and pre-registered whenever 27 
feasible.   28 
17 
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Figure Caption 1 
 2 
Figure 1. The proportion of studies3 replicated at α = .05 (with a bin width of .005). Window 3 
start and end positions are plotted on the horizontal axis. The error bars denote 95% 4 
Jeffreys confidence intervals. R code to reproduce Figure 1 is available from 5 
https://osf.io/by2kc/. 6 
●●
●
●
●
●
●
●
●
●
0.00
0.25
0.50
0.75
1.00
0.000 0.005 0.010 0.015 0.020 0.025 0.030 0.035 0.040 0.045 0.050
Original study p−value
Pr
op
or
tio
n 
of
 st
ud
ies
 re
pli
ca
te
d
number of studies
●
●
●
●
10
20
30
40
View publication stats
